Pollutant-induced activation of the AHR–NF-κB–C/EBPβ axis in colorectal cancer

This study identified environmental pollutants associated with activation of the AHR–NF-κB–C/EBPβ signaling axis and examined their effects in colorectal cancer (CRC). ToxCast indicators and TCGA-COAD/READ RNA-seq data were integrated to construct a pollutant-response matrix; an SVM model prioritized phenmedipham for mechanistic testing. In vitro, phenmedipham increased AHR, p-p65, and C/EBPβ expression and pro-inflammatory cytokine secretion, whereas pathway-component silencing attenuated these effects. In vivo, phenmedipham increased colonic tumor burden and histopathological damage; pathway inhibition mitigated these phenotypes. Immunological analyses indicated impaired dendritic-cell activation and T-cell effector responses. These results provide preclinical evidence that phenmedipham can modulate inflammatory signaling and tumor-associated phenotypes in the tested models. They do not establish human carcinogenicity, CRC risk, or population-level exposure–disease causality; epidemiological validation is required.

Authors

Institutions

Publication Details

Journal
npj Precision Oncology
Published
2026-11-06
DOI
https://doi.org/10.1038/s41698-026-01755-w
Primary Topic
Toxic Organic Pollutants Impact
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pollutant-induced activation of the AHR–NF-κB–C/EBPβ axis in colorectal cancer

赵艳, Yangyang Yu, Chao Han, Yang Qin et al.
1 links
npj Precision Oncology
Toxic Organic Pollutants Impact
article

Pollutant-induced activation of the AHR–NF-κB–C/EBPβ axis in colorectal cancer

赵艳, Yangyang Yu, Chao Han, Yang Qin, Hongyuan Yu
article en

Abstract

This study identified environmental pollutants associated with activation of the AHR–NF-κB–C/EBPβ signaling axis and examined their effects in colorectal cancer (CRC). ToxCast indicators and TCGA-COAD/READ RNA-seq data were integrated to construct a pollutant-response matrix; an SVM model prioritized phenmedipham for mechanistic testing. In vitro, phenmedipham increased AHR, p-p65, and C/EBPβ expression and pro-inflammatory cytokine secretion, whereas pathway-component silencing attenuated these effects. In vivo, phenmedipham increased colonic tumor burden and histopathological damage; pathway inhibition mitigated these phenotypes. Immunological analyses indicated impaired dendritic-cell activation and T-cell effector responses. These results provide preclinical evidence that phenmedipham can modulate inflammatory signaling and tumor-associated phenotypes in the tested models. They do not establish human carcinogenicity, CRC risk, or population-level exposure–disease causality; epidemiological validation is required.

npj Precision Oncology
First Hospital of China Medical University (CN), Anshan Hospital (CN), China Medical University (CN)
Good health and well-being
Openalex Percentile: Top 20%
Toxic Organic Pollutants Impact
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon